Detection of BRAF V600 mutations in melanoma: evaluation of concordance between the Cobas® 4800 BRAF V600 mutation test and the methods used in French National Cancer Institute (INCa) platforms in a real-life setting.

Detection of BRAF V600 mutations in melanoma: evaluation of concordance between the Cobas® 4800 BRAF V600 mutation test and the methods used in French National Cancer Institute (INCa) platforms in a real-life setting.

Vemurafenib is approved for the treatment of metastatic melanoma in patients with BRAF V600 mutation. In pivotal clinical trials, BRAF testing has always been done with the approved cobas 4800 BRAF test. In routine practice, several methods are available and are used according to the laboratories us...

Full description

Bibliographic Details
Main Authors: Samia Mourah, Marc G Denis, Fabienne Escande Narducci, Jérôme Solassol, Jean-Louis Merlin, Jean-Christophe Sabourin, Jean-Yves Scoazec, L'Houcine Ouafik, Jean-François Emile, Remy Heller, Claude Souvignet, Loïc Bergougnoux, Jean-Philippe Merlio
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4366252?pdf=render

Internet

http://europepmc.org/articles/PMC4366252?pdf=render

Similar Items